Biotechnology And Pharmaceutical Services Outsourcing Market Size | Companies
The biotechnology and pharmaceutical services outsourcing market size was exhibited at USD 48.25 billion in 2024 and is projected to hit around USD 83.28 billion by 2034, growing at a CAGR of 5.61% during the forecast period 2024 to 2034.
| Report Coverage | Details |
| Market Size in 2025 | USD 50.96 Billion |
| Market Size by 2034 | USD 83.28 Billion |
| Growth Rate From 2024 to 2034 | CAGR of 5.61% |
| Base Year | 2024 |
| Forecast Period | 2024-2033 |
| Segments Covered | Service, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America, Europe, Asia Pacific, Latin America, MEA |
| Key Companies Profiled | The Quantic Group; IQVIA; Parexel International Corporation; Lachman Consultant Services, Inc.; GMP Pharmaceuticals Pty Ltd.; Concept Heidelberg GmbH; LabCorp; Charles River Laboratories; ICON plc; Syneos Health; Lonza; Catalent Inc.; Samsung Biologics |
Rising drug development costs, diminishing internal capabilities, increasing regulatory frameworks, and low-cost service deployment to contract research organizations (CROs), and contract manufacturing organizations (CMOs) are some of the major factors driving market growth.
Post-pandemic, demand for innovative and effective therapies is increasing and driving growth. The rising drug development costs coupled with higher failure rates and growing regulatory pressure also have a significant impact on market dynamics, accelerating market growth rate. Furthermore, well-established CROs, regulatory outsourcing firms, management consulting firms, and contract manufacturers are catering to the complex demands of pharmaceutical and biotechnological sectors. Contract research and manufacturing companies are investing in personnel, infrastructure, and technology to acquire a significant share of the healthcare outsourcing market.
Increasing demand due to the ongoing patent cliff of biotechnology drugs is anticipated to fuel demand. An increasing number of end-to-end service providers, to meet the rising demand for low-cost drug development and manufacturing, is further anticipated to propel market growth. Moreover, novel drug delivery mechanisms and new product launches are anticipated to drive outsourcing demand. Many companies are opting for outsourcing owing to increasing competition in the healthcare industry. For instance, in February 2024, Lonza completed expansion of its conjugation facility in Visp, Switzerland.
The expansion included the addition of manufacturing suites & supporting infrastructure, increasing development & manufacturing capacity for bioconjugates & antibody-drug conjugates for preclinical, clinical, & commercial supply. An increasing number of R&D activities for new drug development, combination products, and other advanced medicines have increased demand for contract biotechnology and pharmaceutical services. Currently, the global pharmaceutical industry has the second-highest R&D intensity measures of any sector, which indicates that spending on R&D is increasing, and overall spending is likely to grow during the forecast period. For instance, in 2024, the 10 major pharmaceutical companies invested over USD 126.9 billion in research and development (R&D), constituting 41% of the overall research expenditure in the global biopharmaceutical sector for the previous year.
The consulting services segment dominated the market with the largest revenue share of over 24% in 2024. The segment is expected to maintain its position over the forecast period. This can be attributed to increasing M&A activities and constantly changing regulatory protocols. However, the pharma and biotech market has witnessed a continuous entry of new players, such as bioSyntagma, Signa Medical Writing, and Fieve Clinical Research, Inc. These players need to be compliant with set standards and norms, for which consulting is essential as these new entrants lack such capabilities.
The regulatory affairs segment is expected to witness the highest CAGR of 8.37% over the forecast period. Outsourcing trends for regulatory affairs has become an increasingly important practice in the healthcare industry. An increase in geographical expansion activities by companies that aim for speedy approvals in local markets is expected to contribute to the adoption of outsourcing models for regulatory services. Outsourcing market for regulatory affairs is expanding rapidly due to increased R&D activities, rising preference for personalized medicine and biologics augmenting overall volume of clinical trial applications and product registrations.
The pharmaceutical companies segment dominated the market with the largest revenue share 60.0% in 2024. An increase in R&D spending by pharmaceutical companies for development of potential novel products and a rise in investments by CROs for development of core capabilities are expected to drive market demand in the region in the forthcoming years. Contract service providers are recognized as an effective strategic decision to curb the issues of drug shortfall and high production costs, as well as to meet the growing industry demand.
The biotechnology companies segment is expected to witness the fastest CAGR over the forecast period. This growth can be attributed to rapidly expanding biotech product pipelines, along with a trend toward biotechnology entities retaining their assets longer. Moreover, CROs concentrate on adapting their services to smaller biotechnology firms, which have emerged as prominent players in the clinical development of novel medicines and are responsible for driving innovation and expansion.
The biotechnology and pharmaceutical services outsourcing market of North America held a significant market share in 2024. This growth is attributed to the strong presence of several established CROs and CMOs, such as Thermo Fisher Scientific, Catalent, IQVIA, and Samsung Biologics, and growing R&D investments by life sciences and pharmaceutical companies in the region. The strong presence of stringent regulatory policies and a rise in R&D expenditure are among key factors that are likely to boost demand for outsourcing of services by pharmaceutical and biotechnology companies in the region. In addition, the expansion of several CMOs and CROs into the country is projected to propel market growth. For instance, in May 2022, Lonza expanded its inhalation facility at its Tampa (the U.S.) site to improve its capabilities in the development and manufacture of inhaled formulations
U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Trends
The biotechnology and pharmaceutical services outsourcing market in the U.S. held dominant share in North America in 2024. Pharmaceutical and biotechnology companies outsource part of their regulatory functions, such as report writing & publishing, clinical trial application services, and product design & maintenance, to regulatory service providers, thereby contributing to market growth. Moreover, outsourcing helps a company focus more on its core capabilities and improve its service delivery, thereby providing competitive advantage.
Asia Pacific Biotechnology And Pharmaceutical Services Outsourcing Market Trends
The biotechnology and pharmaceutical services outsourcing market in Asia Pacific region dominated the global market in 2024 and accounted for the largest share of over 40.00% of the overall revenue. The regional growth is owing to a rise in investments by developed countries and various regulatory reforms in clinical trial evaluation to align with the standards of various countries investing in the region. Low cost of drug development & manufacturing and availability of a skilled workforce is likely to foster contract development and manufacturing in this region. Moreover, economic policy reforms in countries, such as China, are anticipated to create an open and balanced economy, which presents ample growth opportunities for market players to invest in this region. For instance, in August 2022, Porton Advanced Solutions, a Chinese CDMO entity, raised USD 80 million to advance the cell and gene therapy platform.
The China biotechnology and pharmaceutical services outsourcing market held the largest share in 2024 in Asia Pacific. The country’s market growth is owing to entry of new players and service providers in the country, which can be attributed to stringent standards around patient safety in conducting clinical trials, easy access to a large patient pool, and cheap labor. In addition, low operating cost, increasing investments to improve technology, high R&D capacity, and rising adoption of global R&D standards to meet international requirements are some of the key factors responsible for the growing demand for regulatory & consulting services in China.
The biotechnology and pharmaceutical services outsourcing market in Japan is expected to grow substantially over the forecast period. Rising R&D costs prompt companies to outsource various stages of drug development to reduce expenses and focus on core competencies. Demand for specialized expertise in navigating complex regulatory requirements and advancing technologies drives outsourcing to contract research and manufacturing organizations in the country.
The India biotechnology and pharmaceutical services outsourcing market is anticipated to grow at the fastest CAGR over the forecast period. Cost benefits, improvements in infrastructure, and availability of expertise are some of the major factors driving growth of biotechnology/pharmaceutical services outsourcing market in the country. Western companies outsource their business processes to Asian countries such as India to gain competitive edge.
Europe Biotechnology And Pharmaceutical Services Outsourcing Market Trends
The biotechnology and pharmaceutical services outsourcing market in Europe is growing due to the demand for advanced medicines, which can be attributed to rising incidence of chronic & communicable diseases and rapidly aging population. Increase in consumption of advanced medicines is boosting the need for support from CROs.
The Germany biotechnology and pharmaceutical services outsourcing market is one of the largest pharmaceutical markets in the world after the U.S., China, Japan, and India and this is one of the major factors responsible for high demand for pharmaceutical and biotechnology contract services in the country. Moreover, Germany is known for its engineering and designing capabilities worldwide, hence services such as product design, consulting, product maintenance, and others are expected to contribute majorly in terms of revenue over the forecast period.
The biotechnology and pharmaceutical services outsourcing market in the UK is growing as the companies are outsourcing business activities to increase cost-efficiency, productivity, and focus on innovation. The companies are using hybrid-sourcing models across the value chain to strengthen their capabilities in areas of data management, logistics management, R&D, and analytics.
Latin America Biotechnology And Pharmaceutical Services Outsourcing Market Trends
Latin America is one of the fastest-growing markets for outsourcing in pharmaceutical and biotechnology industries. The growth of this market can be attributed to various factors such as increase in the number of clinical trials and rise in the number of new players venturing into the medical devices market. Countries such as Brazil, Mexico, Venezuela, and Argentina are contributing to the growth of biotechnology/pharmaceutical services outsourcing market in Latin America.
The Brazil biotechnology and pharmaceutical services outsourcing market is one of the largest pharmaceutical markets in the world owing to the growing demand for pharmaceutical products. Moreover, the number of international pharmaceutical companies in the country has increased owing to easier access to private healthcare, enhanced national healthcare services coupled with improved business regulations, and generic drug market expansion through government policies. Hence, Brazil is expected to contribute considerably to the Latin America market during the forecast period.
MEA Biotechnology And Pharmaceutical Services Outsourcing Market Trends
The increase in the number of R&D projects and pharmaceutical companies in the region is expected to boost market growth during the forecast period. The country is adopting global standards and collaborating with other global CROs to mark its market presence. Moreover, MEA CRO industry offers advantages such as world-class medical facilities, well-developed infrastructure, and low operational cost, thereby boosting market growth.
The Saudi Arabia biotechnology and pharmaceutical services outsourcing market is growing as the establishment of universities focused on biotechnology and increase in the number of clinical research organizations with proven track records of conducting clinical trials are some of the factors driving the industry. Moreover, increase in the number of western-trained experts and rapid rise in healthcare investments are some of the factors expected to propel market growth during the forecast period.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the biotechnology and pharmaceutical services outsourcing market
Service
End-use
Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers